Published in World J Gastroenterol on August 07, 2011
Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. Dig Dis Sci (2012) 2.11
Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. J Hepatol (2012) 1.35
Fructose as a key player in the development of fatty liver disease. World J Gastroenterol (2013) 1.26
Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol (2012) 1.19
Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol (2014) 1.05
Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. Am J Gastroenterol (2016) 1.01
Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care (2012) 0.99
Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease? World J Gastroenterol (2012) 0.96
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci (2013) 0.94
Combination of alcohol and fructose exacerbates metabolic imbalance in terms of hepatic damage, dyslipidemia, and insulin resistance in rats. PLoS One (2014) 0.92
Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol (2014) 0.91
Dietary Quality Indices and Biochemical Parameters Among Patients With Non Alcoholic Fatty Liver Disease (NAFLD). Hepat Mon (2013) 0.90
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.90
How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease? Hepat Mon (2013) 0.88
Epidemiology of fatty liver: an update. World J Gastroenterol (2014) 0.87
Effect of metabolic syndrome on perioperative outcomes after liver surgery: A National Surgical Quality Improvement Program (NSQIP) analysis. Surgery (2012) 0.86
Pediatric non-alcoholic fatty liver disease: New insights and future directions. World J Hepatol (2014) 0.83
Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol (2015) 0.83
Dietary protein affects gene expression and prevents lipid accumulation in the liver in mice. PLoS One (2012) 0.82
Higher dietary choline intake is associated with lower risk of nonalcoholic fatty liver in normal-weight Chinese women. J Nutr (2014) 0.82
Potential for Dietary ω-3 Fatty Acids to Prevent Nonalcoholic Fatty Liver Disease and Reduce the Risk of Primary Liver Cancer. Adv Nutr (2015) 0.81
Preservation of hepatocyte nuclear factor-4α contributes to the beneficial effect of dietary medium chain triglyceride on alcohol-induced hepatic lipid dyshomeostasis in rats. Alcohol Clin Exp Res (2012) 0.81
A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease. Genes Nutr (2014) 0.81
Lifestyle intervention in non-alcoholic fatty liver disease in Chengyang District, Qingdao, China. World J Hepatol (2012) 0.80
Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice. Proc Nutr Soc (2015) 0.79
Effects of physical activity upon the liver. Eur J Appl Physiol (2014) 0.79
Non-alcoholic fatty liver disease in children: focus on nutritional interventions. Nutrients (2014) 0.78
Physical activity support or weight loss counseling for nonalcoholic fatty liver disease? World J Gastroenterol (2014) 0.78
Role of CYP2E1 in mitochondrial dysfunction and hepatic tissue injury in alcoholic and non-alcoholic diseases. Curr Mol Pharmacol (2015) 0.77
Non-alcoholic fatty liver disease is not associated with a lower health perception. World J Gastroenterol (2016) 0.77
Osteoporosis across chronic liver disease. Osteoporos Int (2016) 0.76
Risks of misinterpretation in the evaluation of the effect of fruit-based drinks in postprandial studies. Gastroenterol Res Pract (2014) 0.76
Cellular defense system gene expression profiling of human whole blood: opportunities to predict health benefits in response to diet. Adv Nutr (2012) 0.76
AAV8-mediated Sirt1 gene transfer to the liver prevents high carbohydrate diet-induced nonalcoholic fatty liver disease. Mol Ther Methods Clin Dev (2014) 0.76
High-fat but not sucrose intake is essential for induction of dyslipidemia and non-alcoholic steatohepatitis in guinea pigs. Nutr Metab (Lond) (2016) 0.76
Water Soluble Vitamin E Administration in Wistar Rats with Non-alcoholic Fatty Liver Disease. Open Cardiovasc Med J (2012) 0.76
Short-term aerobic exercise training improves gut peptide regulation in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2016) 0.75
Herbal adaptogens combined with protein fractions from bovine colostrum and hen egg yolk reduce liver TNF-α expression and protein carbonylation in Western diet feeding in rats. Nutr Metab (Lond) (2014) 0.75
Antioxidant vitamins in the context of nonalcoholic fatty liver disease in obese children and adolescents. Rev Paul Pediatr (2013) 0.75
Dmbt1 does not affect a Western style diet-induced liver damage in mice. J Clin Biochem Nutr (2013) 0.75
Cytochrome P450-2E1 promotes fast food-mediated hepatic fibrosis. Sci Rep (2017) 0.75
The Asian Grocery Store-Based Cancer Education Program: Creating New Education Modules. J Cancer Educ (2016) 0.75
Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop. J Nutr Sci (2017) 0.75
A diagnostic model for cirrhosis in patients with non-alcoholic fatty liver disease: an artificial neural network approach. Med J Islam Repub Iran (2014) 0.75
Effects of sex and generation on hepatitis B viral load in families with hepatocellular carcinoma. World J Gastroenterol (2017) 0.75
Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. World J Hepatol (2017) 0.75
Intake of Nutrients, Fiber, and Sugar in Patients with Nonalcoholic Fatty Liver Disease in Comparison to Healthy Individuals. Int J Prev Med (2016) 0.75
Streptozotocin-induced diabetes partially attenuates the effects of a high-fat diet on liver and brain fatty acid composition in mice. Lipids (2013) 0.75
Reversing Advanced Hepatic Fibrosis in NASH: Clearly Possible, but Widely at Hand? Dig Dis Sci (2015) 0.75
Can Diet Help Non-Obese Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD)? J Clin Med (2017) 0.75
Fruit Fiber Consumption Specifically Improves Liver Health Status in Obese Subjects under Energy Restriction. Nutrients (2017) 0.75
Protein and vitamin B6 intake are associated with liver steatosis assessed by transient elastography, especially in obese individuals. Clin Mol Hepatol (2017) 0.75
Non-alcoholic fatty liver disease resolution following sleeve gastrectomy. Surg Endosc (2015) 0.75
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care (1997) 23.95
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Intake of sugar-sweetened beverages and weight gain: a systematic review. Am J Clin Nutr (2006) 13.19
Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA (2004) 11.69
Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation (2006) 11.65
Effects of soft drink consumption on nutrition and health: a systematic review and meta-analysis. Am J Public Health (2007) 10.22
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes (2001) 9.67
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 9.36
The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab (2007) 8.91
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology (2003) 8.75
Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetes Care (2010) 8.52
Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet (2005) 8.49
Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med (1997) 8.43
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem (2004) 7.91
Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: a randomized trial. JAMA (1999) 7.88
Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA (2001) 7.63
The public health and economic benefits of taxing sugar-sweetened beverages. N Engl J Med (2009) 7.48
Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr (2003) 6.83
The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med (2005) 6.23
Updating the evidence that physical activity is good for health: an epidemiological review 2000-2003. J Sci Med Sport (2004) 5.92
Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med (1999) 5.65
Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med (2010) 5.36
Prospective study of major dietary patterns and risk of coronary heart disease in men. Am J Clin Nutr (2000) 5.17
Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med (2000) 4.92
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology (2005) 4.86
AGA technical review on nonalcoholic fatty liver disease. Gastroenterology (2002) 4.61
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology (2002) 4.44
Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2003) 4.05
Exercise, glucose transport, and insulin sensitivity. Annu Rev Med (1998) 4.00
Sweetened beverage consumption and risk of coronary heart disease in women. Am J Clin Nutr (2009) 3.90
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev (2008) 3.83
Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology (2010) 3.73
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol (2010) 3.53
Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology (2003) 3.51
Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes (2005) 3.36
Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol (2008) 3.33
Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology (2002) 3.29
Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut (2008) 3.01
High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes (2002) 2.98
Shifts in patterns and consumption of beverages between 1965 and 2002. Obesity (Silver Spring) (2007) 2.91
Animal models of steatosis. Semin Liver Dis (2001) 2.88
Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology (2009) 2.88
Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol (1985) (2005) 2.86
Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab (1999) 2.78
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology (2004) 2.77
Physical activity in U.S. adults with diabetes and at risk for developing diabetes, 2003. Diabetes Care (2007) 2.68
Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology (2009) 2.66
Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care (2010) 2.61
Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med (2001) 2.58
Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis (2001) 2.56
Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology (2003) 2.52
Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol (2006) 2.49
Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol (2005) 2.46
Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol (2008) 2.45
Objectively measured sedentary time may predict insulin resistance independent of moderate- and vigorous-intensity physical activity. Diabetes (2009) 2.45
Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology (2003) 2.44
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol (1997) 2.38
25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis (2008) 2.36
American College of Sports Medicine position stand. Exercise and type 2 diabetes. Med Sci Sports Exerc (2000) 2.32
Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science (1987) 2.26
Levels of physical activity and inactivity in children and adults in the United States: current evidence and research issues. Med Sci Sports Exerc (1999) 2.14
Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes (2004) 2.08
Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol (2009) 2.04
One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol (2005) 2.04
Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology (2009) 2.02
Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol (2004) 1.98
Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis (2006) 1.96
Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab (2005) 1.90
Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology (2006) 1.90
Physical activity and diabetes prevention. J Appl Physiol (1985) (2005) 1.89
Obesity-associated liver disease. J Clin Endocrinol Metab (2008) 1.86
Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord (1998) 1.76
Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology (2008) 1.74
Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care (2005) 1.73
Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther (2001) 1.73
Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int (2006) 1.73
Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol (2005) 1.71
Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol (2007) 1.69
Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab (2004) 1.68
Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology (2008) 1.68
Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol (2008) 1.68
Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol (2008) 1.64
Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem (2007) 1.63
Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab (2005) 1.62
Weight-loss diets for the prevention and treatment of obesity. N Engl J Med (2009) 1.61
Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care (2005) 1.59
Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther (2006) 1.58
Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition (2006) 1.54
High-monounsaturated-fat diets for patients with diabetes mellitus: a meta-analysis. Am J Clin Nutr (1998) 1.52
Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol (2010) 1.52
Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology (2004) 1.49
Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci (2004) 1.46
Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol (1991) 1.45
Adverse effects of dietary fructose. Altern Med Rev (2005) 1.42
Viral hepatitis C. Lancet (2003) 5.81
Viral hepatitis B. Lancet (2003) 4.86
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem (2004) 3.45
Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int (2009) 3.12
Truth survival in clinical research: an evidence-based requiem? Ann Intern Med (2002) 2.87
A comparison of fibrosis progression in chronic liver diseases. J Hepatol (2003) 2.82
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol (2010) 2.75
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology (2003) 2.66
The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest (2012) 2.62
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol (2005) 2.62
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS (2003) 2.58
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol (2003) 2.19
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol (2004) 2.19
Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? J Hepatol (2003) 2.04
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int (2006) 1.96
NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol (2006) 1.90
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem (2007) 1.84
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol (2013) 1.84
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem (2006) 1.78
Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology (2013) 1.78
Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol (2008) 1.78
From NAFLD in clinical practice to answers from guidelines. J Hepatol (2013) 1.76
Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int (2006) 1.73
Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology (2008) 1.70
Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol (2007) 1.69
Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. Clin Gastroenterol Hepatol (2012) 1.65
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol (2006) 1.63
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol (2005) 1.54
Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. J Infect Dis (2013) 1.49
Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol (2007) 1.49
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.47
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol (2011) 1.47
Liver biopsy: the best standard...when everything else fails. J Hepatol (2009) 1.43
Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am J Roentgenol (2009) 1.42
Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology (2008) 1.40
Is the model of end-stage liver disease (MELD) valid in Israel? A critical analysis of liver transplant waiting list mortality. Isr Med Assoc J (2006) 1.39
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol (2011) 1.36
Solid splenic masses: evaluation with 18F-FDG PET/CT. J Nucl Med (2005) 1.34
Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol (2005) 1.33
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol (2005) 1.27
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology (2004) 1.26
A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2006) 1.21
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol (2010) 1.16
Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol (2002) 1.16
Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology (2006) 1.15
Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard. J Hepatol (2013) 1.15
An overview of nonalcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis (2010) 1.14
Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? Gastroenterology (2005) 1.13
Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS One (2008) 1.13
Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci (2003) 1.08
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS One (2008) 1.05
Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol (2012) 1.04
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol (2013) 1.03
Biomarkers of liver fibrosis. Adv Clin Chem (2008) 1.02
Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. Curr Hepat Rep (2011) 1.01
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med (2013) 1.00
Celiac disease diagnosed in the elderly. J Clin Gastroenterol (2008) 1.00
Plasma bilirubin and gamma-glutamyltransferase activity are inversely related in dyslipidemic patients with metabolic syndrome: relevance to oxidative stress. Atherosclerosis (2009) 1.00
Hirsch index and truth survival in clinical research. PLoS One (2010) 1.00
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Antivir Ther (2010) 0.99
FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev Mol Diagn (2005) 0.98
Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol (2013) 0.98
Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. Hepatology (2015) 0.96
Transjugular intrahepatic portosystemic shunt: current indications, patient selection and results. Isr Med Assoc J (2010) 0.96
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. J Hepatol (2012) 0.95
Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol (N Y) (2011) 0.95
Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J Hepatol (2002) 0.95
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS One (2012) 0.94
Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. BMC Gastroenterol (2011) 0.94
Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. J Hepatol (2006) 0.94
Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System. Am J Clin Oncol (2016) 0.92
Induced hypothyroidism accelerates the regression of liver fibrosis in rats. J Gastroenterol Hepatol (2007) 0.91
Pulmonary manifestations of liver diseases. Semin Cardiothorac Vasc Anesth (2009) 0.91
What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI). Regul Toxicol Pharmacol (2011) 0.91
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J Gastrointestin Liver Dis (2008) 0.90
Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest). Comp Hepatol (2004) 0.89
FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C. Hepatology (2008) 0.89
Portal lymphocytic infiltrate in alcoholic liver disease. Hum Pathol (2002) 0.89
Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol (2011) 0.89
Non-invasive detection of liver fibrosis: Is superparamagnetic iron oxide particle-enhanced MR imaging a contributive technique? Eur Radiol (2002) 0.87
Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. Clin Gastroenterol Hepatol (2008) 0.87
Assessment of liver fibrosis: noninvasive means. Saudi J Gastroenterol (2008) 0.87
Initial experience with urgent adult-to-adult living donor liver transplantation in fulminant hepatic failure. Isr Med Assoc J (2004) 0.87
The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. J Hepatol (2006) 0.86
Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int (2013) 0.86
FibroMAX: towards a new universal biomarker of liver disease? Expert Rev Mol Diagn (2007) 0.86
Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease. Liver Int (2013) 0.86
Applicability and variability of liver stiffness measurements according to probe position. World J Gastroenterol (2009) 0.84
Gliotoxin ameliorates development of fibrosis and cirrhosis in a thioacetamide rat model. Dig Dis Sci (2003) 0.84
Thyroid hormones induce activation of rat hepatic stellate cells through increased expression of p75 neurotrophin receptor and direct activation of Rho. Lab Invest (2010) 0.83
Vascular and biliary abnormalities mimicking cholangiocarcinoma in patients with cavernous transformation of the portal vein: role of color Doppler sonography. J Ultrasound Med (2007) 0.83
The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population. Eur J Gastroenterol Hepatol (2012) 0.83
Diagnostic value of FibroTest with normal serum aminotransferases. Hepatology (2006) 0.83
Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases. Dermatology (2008) 0.82